Old Articles: <Older 8441-8450 Newer> |
|
Pharmaceutical Executive October 1, 2012 Lorrie Luellig |
Defensible Data Disposal With the costs of data storage poised to increase, pharmaceutical companies need to break their pack rat mentality with respect to data. |
Pharmaceutical Executive October 1, 2012 Nicolas Pechet |
Your Local Competitor: A Threat in Emerging Markets? Pharmaceutical companies looking to wrest market share in high growth markets of tomorrow must overcome challenges from a new crop of national champions. |
Pharmaceutical Executive October 1, 2012 Ben Comer |
The Drug Vote 2012 A comparative effectiveness study on the two presidential candidates. |
Pharmaceutical Executive October 1, 2012 J. Michael Nicholas |
Complex Drugs and Biologics: Policy Considerations in Brazil The Brazilian government's policy on biologics doesn't adequately address non-biologic complex drugs. Additional guidance is needed to bring these important medicines to market. |
Pharmaceutical Executive October 1, 2012 William Looney |
Three Ways to the Future Developing a drug is still very much a game of chance: a round puzzle of soft edges, with pieces that rarely fit the hard rectangles of time and money. |
Chemistry World October 8, 2012 Phillip Broadwith |
Europe gives generics merger the green flag Two of the top five global generic medicines manufactures, Watson and Actavis, have been given the go-ahead to merge by the European Commission. |
Chemistry World October 5, 2012 Phhillip Broadwith |
Bayer and Evotec team up on endometriosis Bayer Healthcare and Evotec have agreed to collaborate in their search for drugs for endometriosis, a disease in which cells of the type that normally line the uterus wall grow outside of the womb. |
Chemistry World October 5, 2012 Phillip Broadwith |
Teva pulls generic antidepressant The move was prompted by an FDA investigation into whether the generic version (Budeprion XL, made by Impax and marketed by Teva) is truly therapeutically equivalent to the branded medicine (Wellbutrin XL). |
Chemistry World October 2, 2012 Andrew Turley |
Merck & Co $460m ion channel deal Merck & Co has struck a $460 million deal for rights to certain drug candidates developed by Belgian pharma company Ablynx. Merck will get rights to the monoclonal antibodies found to target a voltage gated ion channel. |
Chemistry World October 1, 2012 Andrew Turley |
Pharma should 'double output by 2022' The President's Council of Advisors on Science and Technology advises that pharmaceutical companies should set a goal of doubling output of 'innovative new medicines that meet critical public health needs' over the next 10 -- 15 years. |
<Older 8441-8450 Newer> Return to current articles. |